KYOWA KIRIN CO. LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,635 JPY | +0.44% |
|
-0.36% | +11.18% |
| Apr. 08 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
| Apr. 03 | Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March | MT |
| Sales 2024 * | 470B 3.04B | Sales 2025 * | 483B 3.12B | Capitalization | 1,410B 9.12B |
|---|---|---|---|---|---|
| Net income 2024 * | 66.41B 429M | Net income 2025 * | 73.56B 476M | EV / Sales 2024 * | 2.3 x |
| Net cash position 2024 * | 330B 2.13B | Net cash position 2025 * | 361B 2.33B | EV / Sales 2025 * | 2.17 x |
| P/E ratio 2024 * |
21.1
x | P/E ratio 2025 * |
19
x | Employees | 5,974 |
| Yield 2024 * |
2.2% | Yield 2025 * |
2.31% | Free-Float | 45.89% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.44% | ||
| 1 week | -0.36% | ||
| Current month | -2.06% | ||
| 1 month | -8.65% | ||
| 3 months | +10.85% | ||
| 6 months | +7.62% | ||
| Current year | +11.18% |
1 week
2 623.50
2 679.00
1 month
2 578.002 899.50
Current year
2 266.503 009.00
1 year
2 266.503 110.00
3 years
2 266.504 240.00
5 years
1 674.004 240.00
10 years
1 094.004 240.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 86-03-31 | |
Masashi Miyamoto
PSD | President | 64 | 85-03-31 |
| Chief Tech/Sci/R&D Officer | 62 | 10-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Oyamada
BRD | Director/Board Member | 68 | 21-02-28 |
Yoshihisa Suzuki
BRD | Director/Board Member | 68 | 22-02-28 |
| Director/Board Member | 66 | 08-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.22% | 15 M€ | +4.35% | ||
| 0.44% | 11 M€ | +11.57% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2,635 | +0.44% | 1,033,500 |
| 24-04-17 | 2,624 | -1.26% | 937,200 |
| 24-04-16 | 2,657 | -0.47% | 1,019,100 |
| 24-04-15 | 2,670 | -0.45% | 940,800 |
| 24-04-12 | 2,682 | +1.40% | 1,121,700 |
Delayed Quote Japan Exchange, April 18, 2024 at 02:00 am EDT
More quotes
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,635
JPY
Average target price
3,067
JPY
Spread / Average Target
+16.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.18% | 9.08B | |
| -15.94% | 4.57B | |
| +18.47% | 3.9B | |
| +1.89% | 3.69B | |
| +28.61% | 2.62B | |
| -24.63% | 2.34B | |
| -29.37% | 2.14B | |
| +2.55% | 1.84B | |
| -0.50% | 1.64B | |
| -0.24% | 1.59B |
- Stock Market
- Equities
- 4151 Stock
